DEFONEOS — UK Sovereign Public Services OS
96 AI capability mappings × 6 MCP integrations — MHRA Medicines and Healthcare Products Regulatory Agency
Automated validation of medicine marketing authorisation applications against Human Medicines Regulations 2012, including GMP certification, pharmacovigilance plans, and risk management protocols.
Detection of licensing application deficiencies, safety signal patterns, and compliance gaps via submission data analysis against MHRA regulatory thresholds.
NLP analysis of Summary of Product Characteristics, Patient Information Leaflets, and clinical study reports against MHRA licensing guidelines.
Medicines approval outcome prediction from clinical trial data quality, therapeutic novelty, and regulatory pathway risk scoring.
Clinical trial evidence, pharmacovigilance data, and regulatory precedent into marketing authorisation decision dossiers.
Extraction from MA applications, variations, renewals, and parallel import licences for regulatory tracking.
Licensing pipeline dashboards showing application throughput, approval rates, and therapeutic area trends.
Active substance review tracking, MRP/DCP procedure timelines, and regulatory milestone monitoring.
UKCA marking compliance validation against Medical Devices Regulations 2002, including conformity assessment routes, clinical evidence requirements, and post-market surveillance obligations.
Detection of device safety concerns via adverse event reports, field safety corrective actions, and manufacturer complaint pattern analysis.
Analysis of device technical documentation, clinical evaluation reports, and IFU against UK MDR classification rules.
Device safety incident prediction from classification, intended purpose, and post-market surveillance data patterns.
Clinical evidence, performance data, and post-market surveillance into UKCA conformity assessment dossiers.
Extraction from Declaration of Conformity, technical files, and vigilance reports for regulatory compliance.
Device regulatory dashboards showing UKCA applications, classification trends, and vigilance case volumes.
Device incident reporting, FSCA publication tracking, and conformity assessment timeline monitoring.
Clinical Trials Regulation compliance validation against Medicines for Human Use (Clinical Trials) Regulations 2004, including Ethics Committee approval, GCP requirements, and safety reporting obligations.
Detection of clinical trial protocol deviations, safety signal emergence, and sponsor compliance deficiencies via trial monitoring data.
NLP parsing of trial protocols, Investigator Brochures, and IRB submissions against MHRA GCP inspection findings.
Trial success probability from phase design, endpoint selection, patient population, and regulatory precedent scoring.
Trial data, safety reports, and ethics committee opinions into clinical trial authorisation dossiers.
Extraction from CTAs, substantial amendments, end-of-trial notifications, and GCP inspection reports.
Clinical trial dashboards showing active trials, recruitment rates, and safety reporting compliance.
Trial registration tracking, safety report submission deadlines, and GCP inspection scheduling.
Pharmacovigilance compliance validation against MHRA requirements including ICSR reporting timelines, PSUR submissions, and risk management plan obligations.
Detection of emerging safety signals via Yellow Card scheme data mining, disproportionality analysis, and global safety database integration.
Analysis of adverse event narratives, PSUR safety sections, and RMP risk minimisation measures against MHRA signal management guidance.
Safety signal emergence prediction from prescribing volumes, patient demographics, and pharmacological class risk profiles.
Yellow Card reports, literature evidence, and international safety data into signal evaluation dossiers.
Extraction from ICSRs, PSURs, RMPs, and signal assessment reports for pharmacovigilance tracking.
Drug safety dashboards showing Yellow Card volumes, signal evaluation pipeline, and risk minimisation effectiveness.
Adverse event report processing, PSUR submission tracking, and DHPC publication monitoring.
Blood Safety and Quality Regulations 2005 and Human Tissue (Quality and Safety for Human Application) Regulations 2007 compliance validation.
Detection of blood component quality deviations, tissue processing non-conformances, and transfusion reaction patterns.
Analysis of blood establishment quality documentation, tissue bank SOPs, and adverse reaction reports against MHRA standards.
Blood supply chain risk prediction from donor demographics, seasonal demand patterns, and component wastage trends.
Quality monitoring data, adverse event reports, and inspection findings into blood/tissue safety dossiers.
Extraction from blood establishment authorisations, tissue bank licences, and serious adverse event reports.
Blood and tissue safety dashboards showing compliance rates, adverse event trends, and supply chain metrics.
Blood component quality monitoring, tissue processing compliance tracking, and SAER submission timelines.
Automated classification of products as medicinal, cosmetic, medical device, or food supplement against MHRA borderline guidance and EU-derived definitions.
Detection of unlicensed medicinal products, borderline marketing claims, and classification circumvention via market surveillance.
Analysis of product labelling, marketing claims, and ingredient lists against MHRA borderline guidance documents.
Classification dispute likelihood from product composition, marketing claims, and regulatory precedent analysis.
Product documentation, marketing materials, and scientific evidence into classification decision dossiers.
Extraction from borderline classification precedents, guidance updates, and enforcement notices.
Classification decision dashboards showing borderline case volumes, precedent trends, and enforcement actions.
New product market surveillance, borderline inquiry processing, and guidance publication tracking.
Medicines (Advertising) Regulations 1994 compliance validation for prescription medicine DTC advertising, HCP promotion, and POM-to-P reclassification marketing.
Detection of misleading medicinal claims, unsubstantiated efficacy statements, and off-label promotion via digital advertising monitoring.
NLP analysis of medicine advertisements, promotional materials, and website content against MHRA Blue Guide requirements.
Advertising complaint likelihood from claim type, audience targeting, and regulatory precedent risk scoring.
Advertising materials, clinical evidence, and complaint history into promotional compliance dossiers.
Extraction from ABPI Code breaches, PMCPA adjudications, and MHRA enforcement notices.
Advertising compliance dashboards showing complaint volumes, breach rates, and enforcement trends.
Digital advertising surveillance, promotional material submission tracking, and complaint processing timelines.
Innovation Passport, PRIME designation, and Early Access to Medicines Scheme compliance validation against MHRA accelerated pathway requirements.
Detection of accelerated pathway eligibility risks, data package gaps, and post-approval commitment non-compliance.
Analysis of innovation passport applications, EAMS scientific opinions, and conditional MA documentation against pathway criteria.
Accelerated access success probability from unmet need assessment, data maturity, and regulatory flexibility indicators.
Early clinical evidence, patient group submissions, and benefit-risk assessments into accelerated pathway dossiers.
Extraction from Innovation Passport designations, EAMS opinions, and conditional MA post-approval milestones.
Innovation pipeline dashboards showing accelerated pathway applications, designation rates, and approval timelines.
Innovation passport application tracking, EAMS opinion publication, and conditional MA milestone monitoring.
Medicines Act 1968 enforcement compliance validation including product recall classification, MHRA inspection findings, and criminal prosecution case management.
Detection of counterfeit medicines, illegal online pharmacies, and supply chain integrity breaches via market surveillance data.
Analysis of inspection reports, recall notices, and prosecution case files against MHRA enforcement policy.
Enforcement action likelihood from inspection history, compliance trends, and risk-based prioritisation scoring.
Inspection evidence, laboratory test results, and intelligence reports into enforcement case dossiers.
Extraction from inspection reports, RAPEX notifications, and criminal prosecution case records.
Enforcement dashboards showing recall volumes, inspection outcomes, and prosecution case pipeline.
Product recall tracking, illegal supply chain detection, and enforcement action publication monitoring.
Software as a Medical Device regulatory compliance validation including UKCA classification, clinical evidence requirements, and cybersecurity standards.
Detection of SaMD safety incidents, algorithmic bias risks, and cybersecurity vulnerabilities via post-market surveillance.
Analysis of software technical documentation, AI/ML model validation reports, and cybersecurity risk assessments against MHRA SaMD guidance.
SaMD regulatory pathway risk from software classification, intended use, and algorithmic complexity scoring.
Software validation data, clinical evidence, and cybersecurity assessments into SaMD regulatory dossiers.
Extraction from SaMD technical files, clinical evaluation reports, and cybersecurity compliance documentation.
Digital health regulatory dashboards showing SaMD applications, AI/ML device registrations, and cybersecurity compliance.
SaMD incident reporting, AI/ML model performance monitoring, and cybersecurity threat tracking.
International recognition procedure compliance validation including reliance decisions, MRA partner assessments, and WHO prequalification alignment.
Detection of international regulatory divergence, mutual recognition gaps, and supply chain cross-border compliance risks.
Analysis of international regulatory decisions, WHO guidance, and MRA partner regulatory frameworks against UK requirements.
International recognition success probability from regulatory pathway alignment, data package compatibility, and precedent analysis.
International regulatory decisions, mutual evaluation reports, and harmonisation assessments into recognition dossiers.
Extraction from reliance decisions, MRA implementation reports, and international regulatory correspondence.
International regulatory dashboards showing recognition applications, MRA utilisation rates, and harmonisation progress.
International regulatory change tracking, reliance decision publication, and MRA implementation monitoring.
MHRA obligations under Human Medicines Regulations 2012, Health and Social Care Act 2012, and DHSC ministerial accountability requirements.
PQs, select committee inquiries, and ministerial correspondence for MHRA regulatory performance and drug safety scrutiny.
Hansard debates, committee transcripts, and MHRA annual reports for parliamentary accountability themes.
Parliamentary scrutiny directions from committee composition, health policy priorities, and public concern trends.
Committee evidence, NAO reports, and MHRA annual report data into parliamentary briefings.
Annual reports, government responses to committee recommendations, and ministerial correspondence extraction.
Committee briefings, PQ drafting, and MHRA regulatory policy submissions.
Hansard MHRA mentions, committee schedules, and medicines legislation tracking.